Preclinical models, which are able to recapitulate the biology and pathology of the original individual cancer, are needed to better investigate mechanisms of response and resistance to anticancer therapies. In this respect, novel in vitro models for metastatic colorectal cancer could be of high value. Clin Cancer Res; 24(4); 727–9. ©2017 AACR.
See related article by Luraghi et al., p. 807
http://ift.tt/2HiHzla
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου